The Number of FDA-Approved Autologous CAR T Cell Therapies Continues to Grow!

Bristol Myers Squibb’s Breyanzi Receives FDA Approval. Breyanzi is Cryopreserved in CryoStor® CS10.  On Friday, February 5th, 2021, the U.S. Food and Drug Administration published a press release announcing the approval of CD19-targeting CAR T cell therapy, Breyanzi (lisocabtagene maraleucel; liso-cel). Breyanzi is approved to treat adult patients with relapsed or refractory large B-cell lymphoma…

Read More